On January 15, 2025, the U.S. Department of Health and Human Services Office of Inspector General (“OIG”) posted Advisory Opinion 25-01, a favorable opinion analyzing a pharmaceutical manufacturer’s ...
On this Ropes & Gray podcast, health care partner Michael Lampert and counsel Sam Perrone, and litigation & enforcement partner Andrew O’Connor, rejoin to discuss patient assistance programs, recent ...
Gemtesa’s manufacturer (Urovant Sciences) provides the Gemtesa Simple Savings Program. This is a financial assistance plan aimed at making Gemtesa (vibegron) — a treatment for overactive bladder in ...
Efficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients With Hormone Receptor–Positive Advanced Breast Cancer Eligible patients were diagnosed with cancer and ...
Prescription costs and coverage hurdles are increasing, leading patients to act as their own payers in a fragmented system. Despite $5 billion annual investment in patient assistance programs, less ...
The Alliance for Patient Access, a national advocacy group, has published a report outlining key ways employer-sponsored health plans can benefit from alternative funding programs at the expense of ...
In the rapidly evolving landscape of healthcare, Pharma Patient Assistance Programs (PAP) have been a lifeline for many patients seeking access to essential medications. These programs aim to help ...
Ten case studies were conducted between December 2001 and March 2002 to identify critical issues to be explored more widely in a multistate telephone survey. The case-study sites were selected to ...
The cost of Fabhalta can vary based on several factors, including your insurance coverage and the pharmacy you use. Coupons and drug savings programs can also lower the price you’ll pay for Fabhalta.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results